# Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV

> **NCT02027493** · NA · COMPLETED · sponsor: **National Liver Institute, Egypt** · enrollment: 46 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Reiferon R
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02027493
- **Lead sponsor:** National Liver Institute, Egypt
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-08
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2014-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027493, "Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02027493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*